Clinical Trial Update: An OCT-Guided Variable Dosing Regimen With Ranibizumab for the Treatment of Neovascular AMD [Phase 2]

View source ↗

Summary

An update on a Phase 2 trial evaluating an OCT-guided, variable dosing regimen of ranibizumab for neovascular age-related macular degeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: University of Miami | Conditions: Neovascular Age-related Macular Degeneration | Phase 2 | Status: COMPLETED